Suspension of trading

News Sonnet Biotherapeutics

Stocks

SONN

US83548R4020

Market Closed - Nasdaq Other stock markets 01:00:00 03/12/2025 +04			5-day change	1st Jan Change
1.260 ^USD	-59.35%		-.--%	-

12-17	Sonnet BioTherapeutics Holdings, Inc. Reports Earnings Results for the Full Year Ended September 30, 2025	CI
12-02	Top Midday Decliners	MT

All News

Mentions Relevance

12-17	Sonnet BioTherapeutics Holdings, Inc. Reports Earnings Results for the Full Year Ended September 30, 2025	CI
12-03	Hyperliquid Strategies Inc and Sonnet BioTherapeutics Holdings, Inc. Announce Closing of Business Combination	AQ
12-02	Top Midday Decliners	MT
12-02	Sonnet Biotherapeutics Holdings announces stockholder approval of proposed business combination with Hyperliquid Strategies	RE
12-02	Sonnet BioTherapeutics Holdings, Inc. Announces Stockholder Approval of Proposed Business Combination with Hyperliquid Strategies Inc	AQ
12-02	Sonnet BioTherapeutics Holdings, Inc.(NasdaqCM:SONN) dropped from NASDAQ Composite Index	CI
11-18	Sonnet BioTherapeutics Holdings, Inc. Announces Adjournment of Special Meeting	AQ
15/10/25	Evaluation of SON-1010 Using a Patient-Derived Tumoroid Platform to Support an Ongoing Phase 1 Study in Patients with Sarcoma	AQ
15/10/25	Sonnet BioTherapeutics Holdings, Inc. Collaborates with Spanishos on Non-Clinical Study Using New Alternate Methodologies Based Patient-Derived Tumoroid Platform	CI
19/09/25	Sonnet to Present at the MedInvest Biotech & Pharma Conference	AQ
14/08/25	Sonnet BioTherapeutics Holdings, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended June 30, 2025	CI
12/08/25	Sonnet Releases Virtual Investor What This Means Segment	AQ
11/08/25	Sonnet Releases Virtual Investor "What This Means" Segment	AQ
11/08/25	Sonnet BioTherapeutics Holdings, Inc. Announces Expansion of Its Clinical Study of Patients with Platinum-Resistant Ovarian Cancer	CI
04/08/25	Sonnet BioTherapeutics Expanding Ovarian Cancer Drug Study	MT
04/08/25	Sonnet Biotherapeutics expands trial of SON-1010 with atezolizumab in advanced ovarian cancer	RE
04/08/25	Sonnet BioTherapeutics Expands Clinical Evaluation of SON-1010 Dose Escalation with Atezolizumab in Ovarian Cancer	AQ
04/08/25	Sonnet BioTherapeutics Holdings, Inc. Expands Clinical Evaluation of SON-1010 Dose Escalation with Atezolizumab in Ovarian Cancer	CI
14/07/25	Sonnet Biotherapeutics, Inc Announces $888 Million Business Combination with Rorschach I LLC to Create Entity to Be Named Hyperliquid Strategies Inc	CI
14/07/25	Sonnet Biotherapeutics, Inc. announces $888 million business combination to launch a hype cryptocurrency treasury reserve strategy	RE
14/07/25	Sonnet BioTherapeutics, Inc. Announces $888 Million Business Combination to Launch a HYPE Cryptocurrency Treasury Reserve Strategy	AQ
14/07/25	Sonnet BioTherapeutics Holdings, Inc. announced that it has received $5.5 million in funding	CI
11/07/25	Sonnet BioTherapeutics Holdings, Inc. announced that it expects to receive $310.23499 million in funding	CI
07/07/25	Top Premarket Gainers	MT
30/06/25	Sonnet BioTherapeutics Holdings, Inc. announced that it has received $2.05 million in funding	CI